samedan logo

home > news > detailed info

Ubiquigent celebrates milestone anniversary of DUBprofiler™ compound profiling platform


Dundee, UK, 14th December 2021 – Today, Ubiquigent Limited (Ubiquigent) celebrates the 10th anniversary of its DUBprofiler™ compound profiling platform, together with KSQ Therapeutics joining its expanding customer base.

Over the last 10 years Ubiquigent has profiled thousands of compounds across hundreds of studies on behalf of research groups located within pharma and biotech companies as well as many academic institutions. These groups share the common goal of seeking to identify novel deubiquitylase (DUB) enzyme inhibitors as potential new therapeutics.

KSQ Therapeutics approached Ubiquigent to evaluate a number of its novel compounds, one of which has subsequently become the first DUB inhibitor to enter clinical development. Ubiquigent rapidly profiled KSQ’s compounds across its full DUBprofiler™ enzyme panel, demonstrating their inhibition of USP1 and selectivity profile.

DUBprofiler™ is one of the most highly cited and comprehensive deubiquitylase (DUB) enzyme profiling platforms available. Its constantly expanding panel of human DUB enzymes is one of the most efficient ways to identify novel DUB inhibitors and establish their selectivity and potency.

DUBprofiler™ forms a key part of Ubiquigent’s Drug Discovery Screening Platform and is typically the first step in the evaluation of potential modulators of DUBs. Once profiled, compounds can be rapidly advanced into other DUB focused cell-based assays such as DUBprofiler-Cell™ to determine compound-cellular DUB target engagement and DUB selectivity in cells, as well as into custom assays designed to address target-specific questions.

Ubiquigent’s CEO, Jason Mundin commented: “This milestone anniversary for Ubiquigent is testament to those within our company who recognised the emerging need for a robust platform that could support the development of DUB-targeting compounds. We look forward to continuing to develop the DUBprofiler™ platform alongside our other capabilities to support those working in this developing field. We would also like to wish KSQ Therapeutics every success with their programme as it progresses through the clinic”.
phone +44 (0) 1382 472654
email University Incubator Dundee Technopole James Lindsay Place Dundee DD1 5JJ Scotland, UK
Print this page
Send to a friend
News and Press Releases

Artificial Intelligence Proves Successful in Accelerating Leprosy Detection

Basel, February 16, 2022 — An international team of scientists, led by Instituto Oswaldo Cruz (IOC/Fiocruz), Microsoft’s AI for Health team and the Novartis Foundation, has developed an AI-enabled diagnostic assistant that can help identify suspected leprosy lesions. The tool, called AI4Leprosy, works by assessing skin lesion images in combination with patient symptoms.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

Industry Events

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022)

20-21 June 2022, Berlin, Germany

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022) is held on June, 20-21, 2022 in Berlin, Germany. The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies to discuss the manufacturing and packaging processes of the pharmaceutical industry. Among the participating companies are Bayer, Sandoz, Merck, Novartis, Roche, Genveon, Samsung Biologics, Pfizer.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement